Month: May 2023

MONACO, May 15, 2023 (GLOBE NEWSWIRE) — Costamare Inc. (“Costamare” or the “Company”) (NYSE: CMRE) today reported unaudited financial results for the first quarter ended March 31, 2023 (“Q1 2023”).PROFITABILITY AND LIQUIDITYQ1 2023 Net Income available to common stockholders of $141.6 million ($1.16 per share). Q1 2023 Adjusted Net Income available to common stockholders1 of $46.5 million ($0.38 per share). Q1 2023 liquidity of $1,076.0 million2.DRY BULK OPERATING PLATFORMFirst full operational quarter of Costamare Bulkers Inc. (“CBI”). CBI has currently fixed a fleet of 51 dry bulk vessels on period charters, consisting of:31 Newcastlemax/Capesize vessels 19 Kamsarmax/Panamax vessels 1 Ultramax vessel39 of the chartered-in vessels have been delivered to CBI. Majority of the fixed fleet on index linked charter-in...

Dorel Juvenile continues to gain market share despite overall market weakness in key markets; innovative new products launched Dorel Home sales decline as retailers reduce inventories amid industry softness Network security incident impacts revenue and net incomeMONTREAL, May 15, 2023 (GLOBE NEWSWIRE) — Dorel Industries Inc. (TSX: DII.B, DII.A) today announced results for the first quarter ended March 31, 2023.     Revenue from the first quarter from continuing operations was US$333.2 million, down 22.2%, from US$428.0 million a year ago. Reported and adjusted net loss1 from continuing operations was US$31.5 million or US$0.97 per diluted share compared to the reported net loss from continuing operations of US$27.2 million or US$0.84 per diluted share a year ago. Adjusted net loss1 from continuing operations for the first quarter...

Gross Profit Improves as Company Shifts Strategy to Focus on Higher-Margin Partnerships and Products Increased Capacity from Edible Garden Heartland Allows Company to Become Less Dependent on Third-Party Contract Growers; Expected to Positively Impact Margins Achieves Record Revenue in April; Projects Revenue Growth in Excess of 20% in 2023 Conference Call to Be Held Today at 8:00 AM ET. BELVIDERE, N.J., May 15, 2023 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, today provided a business update and reported financial results for the three months ended March 31, 2023. Mr. Jim Kras, Chief Executive Officer of Edible Garden, stated, “The Company’s revenue...

MIGDAL HAEMEK, Israel, May 15, 2023 (GLOBE NEWSWIRE) — Tower Semiconductor (NASDAQ: TSEM & TASE: TSEM) reports today its results for the first quarter ended March 31, 2023. First Quarter of 2023 Results Overview Revenue for the first quarter of 2023 was $356 million. Revenue for the first quarter of 2022 was $421 million, and for the fourth quarter of 2022 was $403 million. Gross profit for the first quarter of 2023 was $96 million. Gross profit for the first quarter of 2022 was $105 million, and for the fourth quarter of 2022 was $125 million. Operating profit for the first quarter of 2023 was $89 million. Operating profit for the first quarter of 2022 was $63 million. This increase includes there structuring income, net from the previously disclosed reorganization and restructure of our Japan operations during 2022, as in...

Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, will discuss its financial results for the quarter ended March 31, 2023, and provide a business update on its conference call today. First Quarter and Recent Business Highlights:PDS0101 Lead Drug CandidateVERSATILE-002 Phase 2 open-label, multicenter study of PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with human papillomavirus (HPV) 16-positive recurrent and/or metastatic head and neck cancerAnnounced poster presentation...

Company to host conference call today at 8:30 a.m. ET BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter ended March 31, 2023. “The first quarter saw the achievement of a significant milestone for our investigational drug, roluperidone, and for Minerva, as the U.S. Food and Drug Administration (FDA) filed our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms of schizophrenia on April 27, 2023. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26, 2024.  We believe roluperidone has a unique mechanism of action and is intended...

TORONTO, May 15, 2023 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) today announces its financial results for the three months ended March 31, 2023, and provides an update on the Company’s activities at the Valentine Gold Project (the “Project”) in the central region of Newfoundland and Labrador (“NL”). First Quarter Financial Results (all figures are in Canadian dollars unless otherwise noted):Cash and cash equivalents at March 31, 2023 of $130 million; Capital Expenditures of $61 million for the three months ended March 31, 2023, including $52 million related to construction of the Project; The Project’s cost-to-complete, including contingency, was estimated at $463 million at October 31, 2022 and C$403 million at March 31, 2023, reflecting a variance trend of +$4 million on the estimated...

U.S. FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC in April 2023 Announces $10 million strategic investment in commercial-scale alpha-emitting isotope manufacturer, Ionetix Alpha Corp. INDIANAPOLIS, May 15, 2023 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the first quarter ended March 31, 2023 and provided a business update. “As excitement in the clinical and commercial potential of radiopharmaceuticals grows, POINT continues to expand the breadth and depth of our next-generation radioligand platform,” said Joe McCann, Ph.D., CEO of POINT Biopharma. “In Q1 we focused on addressing potential bottlenecks that...